<DOC>
	<DOCNO>NCT02834130</DOCNO>
	<brief_summary>Severe form hemophilia constitutional bleeding disorder represent group rare disease . In last decade , news therapy dramatically increase life expectancy joint 's protection . The investigator propose set single-centre , descriptive , transversal pilot study , design inclusion around thirty child 2 10 year , haemophilia ally hereditary bleeding disorder ( HBD ) , refer Hemophilia Treatment Center ( HTC ) Marseille diagnosis . For child able benefit totality part device accompany diagnostic announcement past 10 year .</brief_summary>
	<brief_title>Input Multidisciplinary Device Accompany Announce Diagnosis Young Children With Serious Constitutional Hemorrhagic Disease Their Families</brief_title>
	<detailed_description>Severe form hemophilia constitutional bleeding disorder represent group rare disease . In last decade , news therapy dramatically increase life expectancy joint 's protection . The recurrence joint bleeding responsive multifocal arthropathy natural history , nowadays , orthopedic outcome good thanks prophylactic treatment . However , announcement diagnosis hereditary bleeding disorder young age represent real psychological trauma parent . Such announcement may induce psycho-developmental impairment . An innovative support implement Hemophilia Treatment Center Marseille , conjunction French Hemophilia Society . This program base multidisciplinary partnership favor psychological support reinsurance parent . With Rare Diseases Foundation support , investigator initiate pilot study include 20 patient severe hemophilia constitutional bleeding disorder , benefit device . This descriptive , monocentric , interventional study permit describe psychological status , quality life patient parent , also evaluate impact device initiation observance treatment like Long Term Prophylaxis .</detailed_description>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<criteria>Patients age 3 12 year Patients diagnose treat Center inclusion Patients FVIII : C &lt; 2 % FIX : C &lt; 2 % FVII : C &lt; 2 % FXIII : C &lt; 2 % fibrinogen &lt; 0,2 g/l , type 3 von Willebrand diseases Thrombasthenia Glanzmann diseases . Patient participate multidisciplinary support announcement diagnosis device Voluntarily give fully inform write signed consent obtain studyrelated procedure conduct Patient clot disorder disease . Patient diagnose treat centre Patient psychiatric disorder disease Patient severe chronic disease</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>